Emtricitabine

證據等級: L5

預測適應症: 3 個

Note before the report: this Evidence Pack has an unusual profile — the top-ranked predicted indication is simian immunodeficiency virus infection (an animal-model disease, not a human clinical indication), original indication/MOA fields are data gaps, and the drug is unregistered in South Africa. I’ve flagged this transparently in the report rather than glossing over it.

Emtricitabine: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) internationally approved for HIV-1 infection as part of antiretroviral therapy; this specific Evidence Pack does not contain original-indication or SAHPRA licensing data for it. The TxGNN model predicts a link to Simian Immunodeficiency Virus (SIV) Infection, but this is a non-human primate disease model rather than a human clinical target, supported only by 2 clinical trials (neither testing emtricitabine directly) and 20 publications (mostly macaque pre-exposure prophylaxis studies).

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack (no SAHPRA license text); internationally approved for HIV-1 infection as part of combination antiretroviral therapy
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.92%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, emtricitabine is an NRTI that inhibits the reverse transcriptase of lentiviruses; its efficacy in HIV-1 infection (including pre-exposure prophylaxis, PrEP) is well established internationally.

SIV is the macaque-model analogue of HIV, and its reverse transcriptase shares high homology with HIV’s — this is almost certainly why the TxGNN knowledge graph placed the two nodes close together, producing a very high similarity score (0.999). However, SIV infection itself is an animal-model disease, not a human clinical indication that SAHPRA (or any regulator) could approve a product for. The supporting literature consistently reflects this: nearly all cited studies are macaque PrEP/chemoprophylaxis experiments using emtricitabine (usually combined with tenofovir) to prevent SHIV/SIV acquisition — i.e., evidence reinforcing emtricitabine’s existing human HIV-PrEP role, not evidence of a new “SIV treatment” indication.

Given this, the prediction is best read as the model correctly recognizing HIV/SIV mechanistic proximity, rather than surfacing a genuinely novel, actionable human indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00863668	N/A	Withdrawn	0	Studied raltegravir (not emtricitabine) HIV/SIV decay kinetics; withdrawn with zero enrollment — low relevance, likely a knowledge-graph adjacency artifact
NCT03577782	Phase 1/2	Unknown	12	Studied vedolizumab + antiretroviral therapy for HIV virological remission; does not test emtricitabine specifically, very small cohort

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20874040	2010	RCT/Review	Pharmacotherapy	Reviews systemic HIV pre-exposure prophylaxis evidence (incl. iPrEx-related human data); supports established FTC/TDF PrEP use, not SIV treatment specifically
39632836	2024	Animal Study	Nature Communications	Oral FTC/TAF plus long-acting cabotegravir/rilpivirine achieved SHIV remission in macaques with early treatment initiation
31362305	2019	Animal Study	J Infect Dis	Oral TAF/FTC combination prevented vaginal SHIV infection in macaques (PrEP model)
29788316	2018	Animal Study	J Infect Dis	Vaginally administered FTC/tenofovir gel protected macaques against repeated rectal SHIV exposure (cross-compartment protection)
27465645	2016	Animal Study	J Infect Dis	Oral FTC + tenofovir alafenamide chemoprophylaxis protected macaques from rectal SHIV infection
26743846	2016	Animal Study	J Infect Dis	Combination FTC/TDF prevented vaginal SHIV infection in macaques even with Chlamydia/Trichomonas coinfection
24914761	2014	Animal Study	AIDS Res Hum Retroviruses	HIV vaccine combined with partial oral FTC/TDF PrEP prevented SHIV infection in macaques and primed immunity
23633402	2013	Animal Study	J Infect Dis	Oral FTC/TDF prevented transmission of a tenofovir-resistant SHIV strain (K65R mutation) in macaques
18216122	2008	Basic Virology	J Virology	Examined SIVagm dynamics in African green monkeys under tenofovir/emtricitabine ART; natural-host model without disease progression
12021341	2002	Basic Virology	J Virology	M184V resistance mutation reduced SIV fitness/virulence in macaques treated with lamivudine or emtricitabine

South Africa Market Information

Emtricitabine is currently not registered with SAHPRA (0 licenses on record in this Evidence Pack).

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA. (Key warnings, contraindications, and drug-interaction data were not available in this Evidence Pack — flagged as a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication — SIV infection — is a non-human primate disease model, not a valid human clinical target, and evidence level is L4 (mechanistic/preclinical only). No trial or publication directly tests emtricitabine’s efficacy against SIV as a treatment indication; all relevant literature instead supports emtricitabine’s existing human HIV-PrEP role.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) — warnings, contraindications, DDI (currently Blocking data gap, DG001)
Confirmed mechanism of action data from DrugBank (DG002)
Reassessment of whether the intended repurposing target should instead be a human-equivalent indication (e.g., HIV-1 PrEP or treatment), since “SIV infection” itself is not a regulatable human indication
SAHPRA registration/import pathway assessment, since the drug is currently not marketed in South Africa
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.